The effect of statins on valve function and calcification in aortic stenosis: A meta-analysis

Atherosclerosis

Volumn 246, Issue , 2016, Pages 318-324

  Zhao, Ying ^a   Nicoll, Rachel ^b   He, Yi hua ^a   Henein, Michael Y ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

Aortic valve stenosis; Meta analysis; Statins

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

AORTA VALVE; AORTA VALVE STENOSIS; AORTIC VALVE AREA; AORTIC VALVE CALCIFICATION; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; FOLLOW UP; HEART FUNCTION; HEART VALVE REPLACEMENT; HUMAN; MEAN VALVE GRADIENT; META ANALYSIS; PEAK VALVE GRADIENT; PEAK VALVE VELOCITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VALVULAR HEART DISEASE; AGED; AORTIC VALVE; AORTIC VALVE STENOSIS; BLOOD; CALCINOSIS; CHI SQUARE DISTRIBUTION; DRUG EFFECTS; FEMALE; HEMODYNAMICS; MALE; MIDDLE AGED; MORTALITY; ODDS RATIO; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AORTIC VALVE; AORTIC VALVE STENOSIS; BIOMARKERS; CALCINOSIS; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, LDL; FEMALE; HEMODYNAMICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; TREATMENT OUTCOME;

EID: 84956630040     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.01.023     Document Type: Article

References (43)

1. Nkomo V.T., Gardin J.M., Skelton T.N., Gottdiener J.S., Scott C.G., Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006, 368:1005-1011.
2. Bridgewater B., Kinsman R., Walton P., Gummert J., Kappetein A.P. The 4th European Association for Cardio-thoracic Surgery adult cardiac surgery database report. Interact. Cardiovasc. Thorac. Surg. 2011, 12:4-5.
3. Lindroos M., Kupari M., Valvanne J., Strandberg T., Heikkila J., Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur. Heart J. 1994, 15:865-870.
4. Stewart B.F., Siscovick D., Lind B.K., Gardin J.M., Gottdiener J.S., Smith V.E., Kitzman D.W., Otto C.M. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J. Am. Coll. Cardiol. 1997, 29:630-634.
5. Parolari A., Loardi C., Mussoni L., Cavallotti L., Camera M., Biglioli P., Tremoli E., Alamanni F. Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention. Eur. J. Cardiothorac. Surg. 2009, 35:493-504.
6. Helske S., Otto C.M. Lipid lowering in aortic stenosis: still some light at the end of the tunnel?. Circulation 2009, 119:2653-2655.
7. Antonini-Canterin F., Hirsu M., Popescu B.A., Leiballi E., Piazza R., Pavan D., Ginghina C., Nicolosi G.L. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am. J. Cardiol. 2008, 102:738-742.
8. Aronow W.S., Ahn C., Kronzon I., Goldman M.E. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am. J. Cardiol. 2001, 88:693-695.
9. Moura L.M., Ramos S.F., Zamorano J.L., Barros I.M., Azevedo L.F., Rocha-Goncalves F., Rajamannan N.M. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J. Am. Coll. Cardiol. 2007, 49:554-561.
10. Novaro G.M., Tiong I.Y., Pearce G.L., Lauer M.S., Sprecher D.L., Griffin B.P. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001, 104:2205-2209.
11. Rosenhek R., Rader F., Loho N., Gabriel H., Heger M., Klaar U., Schemper M., Binder T., Maurer G., Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004, 110:1291-1295.
12. Shavelle D.M., Takasu J., Budoff M.J., Mao S., Zhao X.Q., O'Brien K.D. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002, 359:1125-1126.
13. Bellamy M.F., Pellikka P.A., Klarich K.W., Tajik A.J., Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J. Am. Coll. Cardiol. 2002, 40:1723-1730.
14. Chan K.L., Teo K., Dumesnil J.G., Ni A., Tam J., Investigators A. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010, 121:306-314.
15. Cowell S.J., Newby D.E., Prescott R.J., Bloomfield P., Reid J., Northridge D.B., Boon N.A., Scottish Aortic S., Lowering Lipid Trial IoRI. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N. Engl. J. Med. 2005, 352:2389-2397.
16. Dichtl W., Alber H.F., Feuchtner G.M., Hintringer F., Reinthaler M., Bartel T., Sussenbacher A., Grander W., Ulmer H., Pachinger O., Muller S. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). Am. J. Cardiol. 2008, 102:743-748.
17. Mohler E.R., Wang H., Medenilla E., Scott C. Effect of statin treatment on aortic valve and coronary artery calcification. J. Heart Valve Dis. 2007, 16:378-386.
18. Panahi Y., Sahebkar A., Taghipour H.R., Dadjou Y., Pishgoo B., Rakhshankhah A.S. Atorvastatin therapy is not associated with slowing the progression of aortic stenosis: findings of a randomized controlled trial. Clin. Lab. 2013, 59:299-305.
19. Pohle K., Maffert R., Ropers D., Moshage W., Stilianakis N., Daniel W.G., Achenbach S. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation 2001, 104:1927-1932.
20. Rossebo A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., Gerdts E., Gohlke-Barwolf C., Holme I., Kesaniemi Y.A., Malbecq W., Nienaber C.A., Ray S., Skjaerpe T., Wachtell K., Willenheimer R., Investigators S. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 2008, 359:1343-1356.
21. Raggi P., Davidson M., Callister T.Q., Welty F.K., Bachmann G.A., Hecht H., Rumberger J.A. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation 2005, 112:563-571.
22. Puri R., Nicholls S.J., Shao M., Kataoka Y., Uno K., Kapadia S.R., Tuzcu E.M., Nissen S.E. Impact of statins on serial coronary calcification during atheroma progression and regression. J. Am. Coll. Cardiol. 2015, 65:1273-1282.
23. Rajamannan N.M., Bonow R.O., Rahimtoola S.H. Calcific aortic stenosis: an update. Nat. Clin. Pract. Cardiovasc. Med. 2007, 4:254-262.
24. Capoulade R., Chan K.L., Yeang C., Mathieu P., Bosse Y., Dumesnil J.G., Tam J.W., Teo K.K., Mahmut A., Yang X., Witztum J.L., Arsenault B.J., Despres J.P., Pibarot P., Tsimikas S. Oxidized phospholipids, Lipoprotein(a), and progression of calcific aortic valve stenosis. J. Am. Coll. Cardiol. 2015, 66:1236-1246.
25. Rathan S., Yoganathan A.P., O'Neill C.W. The role of inorganic pyrophosphate in aortic valve calcification. J. Heart Valve Dis. 2014, 23:387-394.
26. Yang Z.K., Ying C., Zhao H.Y., Fang Y.H., Chen Y., Shen W.F. Mineral metabolism disturbances are associated with the presence and severity of calcific aortic valve disease. J. Zhejiang Univ. Sci. B 2015, 16:362-369.
27. Rajamannan N.M. Calcific aortic stenosis: lessons learned from experimental and clinical studies. Arterioscler. Thromb. Vasc. Biol. 2009, 29:162-168.
28. Avakian S.D., Annicchino-Bizzacchi J.M., Grinberg M., Ramires J.A., Mansura A.P. Apolipoproteins AI, B, and E polymorphisms in severe aortic valve stenosis. Clin. Genet. 2001, 60:381-384.
29. Mohler E.R., Gannon F., Reynolds C., Zimmerman R., Keane M.G., Kaplan F.S. Bone formation and inflammation in cardiac valves. Circulation 2001, 103:1522-1528.
30. Skowasch D., Schrempf S., Wernert N., Steinmetz M., Jabs A., Tuleta I., Welsch U., Preusse C.J., Likungu J.A., Welz A., Luderitz B., Bauriedel G. Cells of primarily extra-valvular origin in degenerative aortic valves and bioprostheses. Eur. Heart J. 2005, 26:2576-2580.
31. Henein M.Y., Koulaouzidis G., Granasen G., Wiklund U., Guerci A., Schmermund A. The natural history of coronary calcification: a meta-analysis from St Francis and EBEAT trials. Int. J. Cardiol. 2013, 168:3944-3948.
32. Houslay E.S., Cowell S.J., Prescott R.J., Reid J., Burton J., Northridge D.B., Boon N.A., Newby D.E., Scottish Aortic S., Lowering Lipid Therapy IoRtI. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart 2006, 92:1207-1212.
33. Arad Y., Spadaro L.A., Roth M., Newstein D., Guerci A.D. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart study randomized clinical trial. J. Am. Coll. Cardiol. 2005, 46:166-172.
34. Henein M.Y., Owen A. Statins moderate coronary stenoses but not coronary calcification: results from meta-analyses. Int. J. Cardiol. 2011, 153:31-35.
35. Schmermund A., Achenbach S., Budde T., Buziashvili Y., Forster A., Friedrich G., Henein M., Kerkhoff G., Knollmann F., Kukharchuk V., Lahiri A., Leischik R., Moshage W., Schartl M., Siffert W., Steinhagen-Thiessen E., Sinitsyn V., Vogt A., Wiedeking B., Erbel R. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 2006, 113:427-437.
36. Yoon H.C., Emerick A.M., Hill J.A., Gjertson D.W., Goldin J.G. Calcium begets calcium: progression of coronary artery calcification in asymptomatic subjects. Radiology 2002, 224:236-241.
37. Nicoll R., Henein M.Y. Arterial calcification: friend or foe?. Int. J. Cardiol. 2013, 167:322-327.
38. Santos-Gallego C.G. HDL: quality or quantity?. Atherosclerosis 2015, 243:121-123.
39. Speidl W.S., Cimmino G., Ibanez B., Elmariah S., Hutter R., Garcia M.J., Fuster V., Goldman M.E., Badimon J.J. Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur. Heart J. 2010, 31:2049-2057.
40. Santos-Gallego C.G., Badimon J.J., Rosenson R.S. Beginning to understand high-density lipoproteins. Endocrinol. Metab. Clin. North Am. 2014, 43:913-947.
41. Santos-Gallego C.G., Rosenson R.S. Role of HDL in those with diabetes. Curr. Cardiol. Rep. 2014, 16:512.
42. Goldbarg S.H., Elmariah S., Miller M.A., Fuster V. Insights into degenerative aortic valve disease. J. Am. Coll. Cardiol. 2007, 50:1205-1213.
43. Parolari A., Tremoli E., Cavallotti L., Trezzi M., Kassem S., Loardi C., Veglia F., Ferrari G., Pacini D., Alamanni F. Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis?. Heart 2011, 97:523-529.